Please login to the form below
Highly Specialised Technology
This page shows the latest Highly Specialised Technology news and features for those working in and with pharma, biotech and healthcare.
NICE approves BioMarin’s Brineura after initial setback
The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE.
Latest news
-
Spinraza managed access deal in England breaks deadlock for Biogen
a prevalence to go through NICE's highly specialised technology (HST) route, which is reserved for the rarest orphan and ultra-orphan treatments. ... Patient groups say the health economics of a rare disease like SMA make it highly unlikely to be passed
-
NICE knocks back BioMarin’s Batten disease drug
The decision, which was published under NICE’s Highly Specialised Technology (HST) committee, marks the end of a year-long negotiation between BioMarin and NHS England. ... Once these elements are excluded, the cost-effectiveness estimates for
-
‘Inflexible’ NICE blocking access to rare disease drugs
NICE has a Highly Specialised Technology (HST) appraisal, which has seen a number of innovative pricing and reimbursement deals done with companies to bring orphan and ultra-orphan drugs to NHS ... patients. However many rare diseases do not qualify for
-
NICE appraisal fees to be introduced despite opposition
The fee for single technology appraisals (STAs) and highly specialised technology appraisals (HTAs) will be £126, 000 ($158, 500, 140, 400).
-
Promising more appraisal capacity, NICE revives industry fee idea
NICE is proposing that bigger companies pay £126, 000 ($160, 000) for a single technology appraisal or a highly specialised technology appraisal (for rare disease drugs), or £94, 500 for smaller ... Industry association the ABPI hasn’t yet responded
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Evolution or revolution: the latest review of NICE methods
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) included a commitment from NICE to scope and initiate a review of the methods for its Technology Appraisal Programme (TAP) ... A broad range of technologies. NICE has said that the
-
#OrkambiNow?
The row boiled over into accusations being traded publicly – Vertex calling the health service budget holder’s stance ‘outrageous’ last summer and NHS England’s head of specialised medicines commissioning John ... The STA system doesn’t
-
Rare diseases: meeting the challenge
NICE, which has its own Highly Specialised Technology (HST) assessment process, has come under fire for the change in April 2017 to the way it assesses therapies to treat the rarest
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- Shionogi's Gram-negative antibiotic launches in the UK
- Eli Lilly reports first results for COVID-19 targeting antibody
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
PMHub
11 London
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
